New Dual-Target antibody tested for safety in humans
NCT ID NCT07439263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety of a single dose of HB2198, an experimental antibody that binds to two immune cell targets (CD19 and CD20). About 32 healthy adults will receive either the drug or a placebo and be monitored for about two months. The goal is to see if the drug is safe and how the body processes it, before testing it in people with diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HB2198 (an experimental antibody that targets CD19 and CD20 proteins on immune cells)
What this could lead to
If safe, this could lead to further studies testing HB2198 for conditions involving B cells, such as autoimmune diseases or certain blood cancers.
What could go wrong
This is a very early Phase 1 trial in only 32 healthy people, so it cannot prove effectiveness. The antibody may cause side effects or fail in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, 3153, Australia